Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025

Image Credit : thriveglobal

The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.

To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/1310

The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% over the forecast period (2017 – 2025).

The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.

Increasing prevalence of multiple sclerosis to augment market growth

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.

Intensive R&D programs undertaken by organizations to accelerate the market growth     

Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1310

The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

You may be interested

Network-as-a-service Market  to See Incredible Growth By 2026
Information Technology and Gadgets
Information Technology and Gadgets

Network-as-a-service Market to See Incredible Growth By 2026

Alex Mathew - April 20, 2018

Network-as-a-service (NaaS) is the network transport connectivity used for delivering network services virtually over the internet on a metered service (pay-per-use). NaaS providers offer necessary network hardware…

Desktop Virtualization Market  to See Incredible Growth By 2025
Information Technology and Gadgets
Information Technology and Gadgets

Desktop Virtualization Market to See Incredible Growth By 2025

Alex Mathew - April 20, 2018

Desktop virtualization is a virtualization technology, which is used to separate a computer desktop environment from physical computers by storing desktop in remote location server. Server virtualization…

Digitally Delivered Services Market  to See Incredible Growth By 2025
Information Technology and Gadgets
Information Technology and Gadgets

Digitally Delivered Services Market to See Incredible Growth By 2025

Alex Mathew - April 20, 2018

Digitally delivered services is an electronic way of delivering information, which includes data and content delivery across various platforms or devices such as web or mobile. These…

Most from this category